Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$0.94 and traded as low as C$0.86. Oncolytics Biotech shares last traded at C$0.93, with a volume of 134,300 shares.
Analyst Upgrades and Downgrades
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
Read Our Latest Report on ONC
Oncolytics Biotech Stock Up 6.1%
The business has a 50-day simple moving average of C$0.72 and a two-hundred day simple moving average of C$0.93. The company has a market cap of C$80.16 million, a price-to-earnings ratio of -2.90 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
